EUVIMEDEUVIMED entdecken
Crossref

Astragaloside IV Pretreatment Alleviates Pulmonary Ischemia–Reperfusion Injury via the TLR4 / MyD88 / NF ‐ κB p65 Pathway in Rats

Xiao-Rui Tian, Jun-Hui Zhao iD, Xia-Hui Yin, Jia-Hui Lin, Si-Min Liang, Xiao-Qing Xu, Ke-Ying Li, Tian-Shuang Fan, Ping Xiong iD

Phytotherapy Research · 2025-10 · 39 (10) · 4744-4765

DOI: 10.1002/ptr.70039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 04.09.2025. Verfasst von Xiao-Rui Tian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering, South China Agricultural University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, Myeloid Differentiation Factor 88, Saponins, Transcription Factor RelA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Special fund for Enterprise Science and Technology commissioner of Guangdong Province, China, Special fund for Science and Technology innovation strategy program of Guangdong Province, China, Co-construction program of Agricultural Science and Technology Cooperation of South China Agricultural University, Guangdong Province, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aim Our previous study confirmed that ASIV can protect the lung from ischemia–reperfusion injury. The aim of this study was to determine whether ASIV attenuates PIRI by inhibiting the activation of the TLR4/MyD88/NF‐κBp65 pathway. Experimental procedure In vitro, the protection of ASIV, TAK‐242, NAC, and DEX to OGD/R‐induced cell injury was compared. In vivo, the PIRI model was induced in SD rats. The lung tissue W/D ratio and pathological morphology, as well as the markers of oxidative stress, were monitored. The mRNA and protein expression levels correlated to the TLR4/MyD88/NF‐κB p65 pathway were evaluated. Furthermore, we performed molecular docking and binding affinity calculations of the interaction between ASIV and TLR4‐MD‐2, which was verified with SPR. Key results and conclusions and implications ASIV showed more effective protection than DEX or NAC, and exhibited a synergistic effect with TAK‐242. After treatment with ASIV, lung tissue and cellular damage were obviously alleviated, and the levels of T‐SOD and GSH‐PX were significantly increased, while lung MDA and MPO decreased. Moreover, the ASIV groups showed a significant down‐regulation of the TLR4, MyD88, NF‐κBp65 and p‐NF‐κBp65 proteins when compared with the PIRI model group. The prediction showed that ASIV can enter the cavity of TLR4‐MD‐2 and exhibit strong binding, with a free binding energy of −8.0 kcal·mol −1 . SPR further confirmed that ASIV rapidly bound to the rhTLR4‐MD‐2 complex with a K D of 2.17 × 10 −6 M. In conclusion, ASIV can specifically bind to rhTLR4‐MD‐2, thus alleviating PIRI by suppressing the activation of the TLR4/MyD88/NF‐κB65‐mediated inflammatory pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 4Myeloid Differentiation Factor 88SaponinsTranscription Factor RelAReperfusion InjuryTriterpenesAnimalsRats, Sprague-DawleyMaleRatsSignal TransductionLungMolecular Docking SimulationOxidative StressSulfonamides

Stichwörter der Autor:innen

ASIVPIRITLR4‐MD‐2protective effect

Substanzen

Toll-Like Receptor 4Myeloid Differentiation Factor 88SaponinsTlr4 protein, ratTranscription Factor RelAMyd88 protein, ratTriterpenesastragaloside ARela protein, ratethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate

Autor:innen und Institutionen

  • Department of Pharmaceutical Engineering, South China Agricultural University, Guangzhou, Guangdong, China.

ORCID-Profile: Jun-Hui Zhao, Ping Xiong

Förderung

  • Special fund for Enterprise Science and Technology commissioner of Guangdong Province, China
  • Special fund for Science and Technology innovation strategy program of Guangdong Province, China
  • Co-construction program of Agricultural Science and Technology Cooperation of South China Agricultural University, Guangdong Province, China
  • National Natural Science Foundation of China (NSFC)

Zitieren

APA

Tian, X. R., Zhao, J. H., Yin, X. H., Lin, J. H., Liang, S. M., Xu, X. Q., Li, K. Y., Fan, T. S., & Xiong, P. (2025). Astragaloside IV Pretreatment Alleviates Pulmonary Ischemia–Reperfusion Injury via the TLR4 / MyD88 / NF ‐ κB p65 Pathway in Rats. Phytotherapy Research, 39(10), 4744-4765. https://doi.org/10.1002/ptr.70039

Vancouver

Tian XR, Zhao JH, Yin XH, Lin JH, Liang SM, Xu XQ, et al. Astragaloside IV Pretreatment Alleviates Pulmonary Ischemia–Reperfusion Injury via the TLR4 / MyD88 / NF ‐ κB p65 Pathway in Rats. Phytotherapy Research. 2025;39(10):4744-4765. doi:10.1002/ptr.70039

BibTeX
@article{Tian2025,
  author = {Tian, Xiao-Rui and Zhao, Jun-Hui and Yin, Xia-Hui and Lin, Jia-Hui and Liang, Si-Min and Xu, Xiao-Qing and Li, Ke-Ying and Fan, Tian-Shuang and Xiong, Ping},
  title = {Astragaloside IV Pretreatment Alleviates Pulmonary Ischemia–Reperfusion Injury via the TLR4 / MyD88 / NF ‐ κB p65 Pathway in Rats},
  journal = {Phytotherapy Research},
  year = {2025},
  volume = {39},
  number = {10},
  pages = {4744--4765},
  doi = {10.1002/ptr.70039}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche